Biliary tract cancers treatment sales will expand through 2035, with targeted therapy at 63.1% of drug class demand and institutional sales at 85.5% of sales channel sales in 2025. The market was valued at USD 372.5 million in 2025 and is forecast to record an 8.2% CAGR between 2025 and 2035.